Sign In to View Organizational & Contract Pricing.
Select a Size
About This Item
Empirical Formula (Hill Notation):
La
CAS Number:
Molecular Weight:
138.91
UNSPSC Code:
12352300
PubChem Substance ID:
MDL number:
InChI
1S/La
SMILES string
[La]
InChI key
FZLIPJUXYLNCLC-UHFFFAOYSA-N
assay
99%
form
foil
manufacturer/tradename
Goodfellow 162-322-95
resistivity
54 μΩ-cm
size × thickness
35 x 47 mm × 0.5 mm
bp
3464 °C (lit.)
mp
920 °C (lit.)
density
6.19 g/mL at 25 °C (lit.)
Looking for similar products? Visit Product Comparison Guide
General description
For updated SDS information please visit www.goodfellow.com.
Legal Information
Product of Goodfellow
Storage Class
4.3 - Hazardous materials which set free flammable gases upon contact with water
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Regulatory Information
新产品
This item has
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Stuart M Sprague
Current medical research and opinion, 23(12), 3167-3175 (2007-11-10)
Obstacles to successful management of hyperphosphatemia in chronic kidney disease include inadequate control of dietary phosphate and non-compliance with phosphate-binder therapy. Three major classes of phosphate binders include calcium-based binders, sevelamer HCl, and lanthanum carbonate. A literature search was performed
M Cozzolino et al.
The International journal of artificial organs, 30(4), 293-300 (2007-05-24)
Phosphate overload is a dramatic consequence in end-stage renal disease (ESRD) patients. Recent studies have well documented that abnormalities in mineral and bone metabolism in these patients are associated with increased cardiovascular morbidity and mortality. Elevated serum phosphate and calcium-phosphate
Tilman B Drüeke
Seminars in dialysis, 20(4), 329-332 (2007-07-20)
Controlling serum phosphorus levels in patients with renal failure is critical. The use of oral phosphate-binding agents is universal for patients with end-stage kidney disease to reduce phosphate absorption. The therapeutic goal is to reduce serum phosphorus levels without disturbing
Gadolinium and lanthanum: a iatrogenic transmetallation?
Simona Brambilla et al.
Clinical biochemistry, 41(13), 1029-1033 (2008-06-19)
Marc E De Broe
Seminars in dialysis, 21(2), 142-144 (2008-02-06)
The recent recognition of gadolinium (Gd) administration as a cause of nephrogenic systemic fibrosis (NSF) is a growing concern. The similarity of Gd and lanthanum (La), based on their place in the table of Mendeljev, has led to assumptions that
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service